| http://purl.uniprot.org/citations/27460435 | http://www.w3.org/1999/02/22-rdf-syntax-ns#type | http://purl.uniprot.org/core/Journal_Citation |
| http://purl.uniprot.org/citations/27460435 | http://www.w3.org/2000/01/rdf-schema#comment | "In order to explore the potential effects of interleukin (IL)-35 on IL-10, transforming growth factor-β (TGF-β), interferon-γ (INF)-γ, IL-12 and IL-17, a pcDNA3.1‑IL-35 plasmid was injected into the vitreous cavity of BALB/c mice. Enzyme-linked immunosorbent assay, western blot analysis and quantitative PCR analysis were performed to confirm the successful expression of IL-35. Slit-lamp biomicroscopy, hematoxylin and eosin staining and immunofluorescence were employed to detect the status of eyes, and western blot analysis was performed to examine the expression of corneal graft rejection-related cytokines. There were no abnormalities in the eyes pre-mydriasis or post-mydriasis and no injuries to the cornea or retina following the injection of IL-35-expressing plasmid. An immunofluorescence assay detected the positive expression of IL-35 in corneal epithelial cells from IL-35‑injected mice and negative staining in the control group. Further study revealed that IL-35 enhanced the expression of IL-10 and TGF-β which reached their highest levels at 1 and 2 weeks after injection, respectively (p<0.01). Moreover, the expression of INF-γ and IL-12 was decreased significantly at 2 weeks after the injection of IL-35-expressing plasmid (p<0.05), and the expression of IL-17 was suppressed notably at 4 weeks after the injection (p<0.05). The intravitreal injection of IL-35-expressing plasmid in mice downregulates the expression of pro-inflammatory cytokines and upregulates the expression of anti-inflammatory cytokines. Thus, IL-35 may further be assessed as a potential target for the treatment of corneal graft rejection."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.org/dc/terms/identifier | "doi:10.3892/ijmm.2016.2688"xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/author | "Huang T."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/author | "Wu Q."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/author | "Hou C."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/author | "Ouyang C."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/date | "2016"xsd:gYear |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/name | "Int J Mol Med"xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/pages | "713-720"xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/title | "Effects of an intravitreal injection of interleukin-35-expressing plasmid on pro-inflammatory and anti-inflammatory cytokines."xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://purl.uniprot.org/core/volume | "38"xsd:string |
| http://purl.uniprot.org/citations/27460435 | http://www.w3.org/2004/02/skos/core#exactMatch | http://purl.uniprot.org/pubmed/27460435 |
| http://purl.uniprot.org/citations/27460435 | http://xmlns.com/foaf/0.1/primaryTopicOf | https://pubmed.ncbi.nlm.nih.gov/27460435 |
| http://purl.uniprot.org/uniprot/#_O35228-mappedCitation-27460435 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/27460435 |
| http://purl.uniprot.org/uniprot/#_Q3U1K3-mappedCitation-27460435 | http://www.w3.org/1999/02/22-rdf-syntax-ns#object | http://purl.uniprot.org/citations/27460435 |
| http://purl.uniprot.org/uniprot/O35228 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/27460435 |
| http://purl.uniprot.org/uniprot/Q3U1K3 | http://purl.uniprot.org/core/mappedCitation | http://purl.uniprot.org/citations/27460435 |